Flow Neuroscience has launched FL-100 in the United States, bringing an FDA-approved at-home transcranial direct-current stimulation treatment to adults with moderate-to-severe major depressive disorder.

The guidance gives sponsors clearer recommendations for addressing trial design, safety monitoring, abuse potential and the operational challenges associated with hallucinogenic drug effects.